Medivolve Inc.
MEDV.NE
CBOE CA0.03
CAD
+0.01
- -
Medivolve Inc.
MEDV.NE
(CBOE CA)
Recent
price
0.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Medivolve Inc. is a Canadian healthcare technology company headquartered in Toronto, Ontario, founded in 2005, that operates primarily in the healthcare technology and telehealth sectors. The company offers a suite of core products and services including a bespoke telehealth platform, a clinical diagnostic network with a network of retail collection sites providing diagnostic testing, vaccinations, and other point-of-care services, and a data-driven artificial intelligence (AI) framework aimed at improving patient care. Its diagnostic testing services encompass COVID-19 testing options such as rapid antibody blood tests, reverse transcription-polymerase chain reaction (RT-PCR) tests, and rapid antigen tests. Medivolve also develops technologies to identify, treat, and prevent medical issues, providing immunity scoring and expanding telehealth services including physician consultations and prescription medications distribution. The company operates through its subsidiaries, including Medivolve Pharmacy Inc., doing business as Marbella Pharmacy. Recent major corporate developments include Medivolve's strategic shift toward building a profitable software as a service (SaaS)-based health technology company by integrating data-driven clinical diagnostics with telehealth and pharmacy services through a streamlined technology network. In early 2024, it entered into a master services agreement for telehealth platform development and established a Management Services Organization (MSO) to coordinate physician/patient interactions, medical billing, practice management, and facilitate access to its diagnostic and pharmacy services, supporting growth in the U.S. healthcare market. Management changes also occurred, including the resignation of the former president and CEO in 2024. Medivolve continues to focus on expanding its clinical diagnostics and telehealth service offerings to address systemic issues in the fragmented and expensive U.S. healthcare system. Medivolve targets markets primarily in the United States and Canada, delivering healthcare solutions to individuals and organizations seeking accurate, affordable, and accessible diagnostic and telehealth services. The company's integrated technology platforms and physical retail sites position it to address gaps in timely testing, diagnostics, and healthcare management through technological innovation and operational expansion, aiming to transform the healthcare delivery experience via data and AI-enabled platforms. The company employs a multidisciplinary leadership team and maintains operations that span clinical testing, telehealth, and pharmacy services with an emphasis on innovation in healthcare technology delivery. This comprehensive focus on telehealth, clinical diagnostics, AI-driven healthcare management, and recent strategic contracts and organizational restructuring define Medivolve's current business and growth model.